Eupraxia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EPRX | EIKN | INVA | TRDA | ENTA | LXRX | |
|---|---|---|---|---|---|---|
| Market cap | 483.66M | 393.24M | 1.55B | 214.15M | 358.24M | 734.18M |
| P/E (TTM) | — | — | 5.0 | — | — | — |
| Forward P/E | -7.1 | -1.1 | 9.7 | -1.8 | -5.2 | -8.7 |
| Price/book | 4.7 | 0.8 | 1.3 | 0.8 | 3.5 | 4.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +23.31% | −50.20% | +25.21% | −2.41% | +8.79% | +16.67% |
| Today | −1.88% | −2.81% | +1.13% | −3.00% | −1.60% | −1.79% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EPRX news ›Eupraxia Pharmaceuticals Showcases EP-104GI EoE Data at Major Gastroenterology Meetings
Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has shared an announcement. The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$19.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see…
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
The randomized, placebo-controlled portion of RESOLVE is recruiting patients at both doses under study. Eupraxia Pharmaceuticals (EPRX) will present three abstracts on its ongoing RESOLVE trial of EP-104GI at upcoming gastroenterology…
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Key New Findings from the RESOLVE Phase 1b/2a Trial Symptom Response and Clinical Remission as Measured by SDI Symptom response is measured in the open-label portion of the RESOLVE study using the Straumann Dysphagia Index (SDI), a measure…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tipranks.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.